Back to top
more

XOMA (XOMA)

(Delayed Data from NSDQ)

$24.08 USD

24.08
32,338

-1.71 (-6.63%)

Updated Jun 3, 2024 04:00 PM ET

After-Market: $24.16 +0.08 (0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for XOMA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

XOMA Corporation [XOMA]

Reports for Purchase

Showing records 261 - 280 ( 330 total )

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 261

03/15/2013

Company Report

Pages: 10

We assume coverage with a $5 price target and a Buy rating,

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 262

03/12/2013

Company Report

Pages: 11

2012 Financials Beat Due To Expense Control;

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 263

03/11/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 264

03/04/2013

Industry Report

Pages: 32

Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 265

01/07/2013

Company Report

Pages: 8

We Believe Gevokizumab Demonstrated Initial Clinical Activity In Severe Inflammatory Acne

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 266

12/14/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of December 16

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 10.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 267

11/30/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of December 3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 268

11/29/2012

Daily Note

Pages: 9

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 269

11/29/2012

Daily Note

Pages: 5

Partner Servier Initiates POC Trial Testing Gevokizumab in Acute Coronary Syndrome Which Could Provide Significant Value to Xoma With Little Risk

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 270

11/29/2012

Company Report

Pages: 4

Partner Servier Starts Gevokizumab Study in CV Indication, as Expected

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 271

11/21/2012

Daily Note

Pages: 16

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 272

11/21/2012

Company Report

Pages: 6

Xmas Come Early; PATH Phase III Study in Hypertension Successful

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 273

11/20/2012

Company Report

Pages: 11

With The Recent Pullback and Cash Runway Through Multiple Transforming Catalysts, We Believe It Is Time To Invest In; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 274

11/08/2012

Daily Note

Pages: 25

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 275

11/08/2012

Company Report

Pages: 7

3Q12 Results; Focus on Gevo Late Stage Studies, Target Reduced to $5

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 276

11/05/2012

Company Report

Pages: 10

Q3 Preview: We Anticipate A Pipeline Update Could Be Material.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 277

10/07/2012

Company Report

Pages: 9

EYEGUARD Phase 3 Program Underway

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 278

10/04/2012

Company Report

Pages: 8

Adds Third Study to Broad Gevokizumab Phase III Program; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 279

09/28/2012

Daily Note

Pages: 15

MORNING CALL SUMMARY.

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: XOMA Corporation

Industry: Medical - Biomedical and Genetics

Record: 280

09/27/2012

Daily Note

Pages: 5

Partner Servier Initiates Phase 3 Gevokizumab Trial in Behcet''s Uveitis and We See Cash Runway Through Important 2013 Milestones

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party